Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity (Details Narrative)

v3.21.2
Shareholders Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 10, 2021
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Aug. 01, 2020
Subsidiary, Sale of Stock [Line Items]              
Common Stock, Shares Authorized   500,000,000 500,000,000 500,000,000   500,000,000  
Preferred Stock, Shares Authorized   50,000,000 50,000,000 50,000,000   50,000,000  
Number of sale of shares       30,559      
Proceeds from sale of stock       $ 115,000      
Shares issued (net of subscription receivable), shares 30,000     26,573 106,291    
Stock-based compensation expense       $ 1,211,543 $ 1,471,508    
Number of shares granted       27,239      
Options outstanding   175,384 175,384 175,384   148,145  
Vesting period       5 years      
Fair value of options granted       $ 74,733      
Fair value assumptions, risk free interest rate       2.00%      
Fair value expected term       5 years      
Fair value assumptions, dividend yield       0.00%      
Fair value assumptions, expected volatility       79.00%      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value   $ 350,000 $ 350,000 $ 350,000   $ 307,000  
Underwriter [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrants exercisable date     Sep. 14, 2024        
Warrants exercise price   $ 5.00 $ 5.00 $ 5.00      
Warrants issued     106,291        
Underwriter [Member] | Interest Expense [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrant expense     $ 198,000        
Minimum [Member]              
Subsidiary, Sale of Stock [Line Items]              
Exercise price of vested shares       0.64      
Maximum [Member]              
Subsidiary, Sale of Stock [Line Items]              
Exercise price of vested shares       $ 2.26      
Sponsorship Agreements [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of shares granted       100,980      
Executives [Member]              
Subsidiary, Sale of Stock [Line Items]              
Shares issued (net of subscription receivable), shares       26,573 106,291    
Stock-based compensation expense       $ 100,000 $ 400,000    
Board Members And Consultants [Member]              
Subsidiary, Sale of Stock [Line Items]              
Stock-based compensation expense       345,000 582,000    
Shares granted for sponsorships       310,000 0    
Employment Agreement [Member]              
Subsidiary, Sale of Stock [Line Items]              
Stock-based compensation expense       $ 57,063 $ 57,063    
Accrued Bonuses Acquisitions And Settlements [Member]              
Subsidiary, Sale of Stock [Line Items]              
Shares issued (net of subscription receivable), shares       502,835      
Founder [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of shares granted       74,404      
Sponsor [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of shares granted       1,550      
Value of shares granted       $ 3,500      
Two Thousand And Twenty Equity Incentive Plan [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of shares reserved             1,913,243
IPO [Member]              
Subsidiary, Sale of Stock [Line Items]              
Stock Issued During Period, Shares, Conversion of Convertible Securities   18,750,000          
Stockholders' Equity, Reverse Stock Split   one for 3.763243 reverse stock split approved by the Company’s board of directors and its shareholders.          
Shares issued (net of subscription receivable), shares   7,187,500          
IPO [Member] | Underwriter [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of securities called by rights   359,375 359,375 359,375      
Warrants exercise price   $ 5.00 $ 5.00 $ 5.00      
IPO [Member] | Minimum [Member] | Underwriter [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrants exercisable date       Mar. 14, 2022      
IPO [Member] | Maximum [Member] | Underwriter [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrants exercisable date       Sep. 14, 2026